A small study showed 2.5 years of aging reversal. The people were 1.5 years younger according to epigenetic markers than when they were first measured one year prior. The trial included two widely used anti-diabetic drugs, dehydroepiandrosterone (DHEA) and metformin, in the treatment cocktail. [Aging Cell – Reversal of epigenetic aging and immunosenescent trends in humans. Study by Horvath of UCLA.]
Epigenetic “clocks” can now surpass chronological age in accuracy for estimating biological age. Here, we use four such age estimators to show that epigenetic aging can be reversed in humans. Using a protocol intended to regenerate the thymus, we observed protective immunological changes, improved risk indices for many age‐related diseases, and a mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment (−2.5‐year change compared to no treatment at the end of the study). The rate of epigenetic aging reversal relative to chronological age accelerated from −1.6 year/year from 0–9 month to −6.5 year/year from 9–12 month. The GrimAge predictor of human morbidity and mortality showed a 2‐year decrease in epigenetic vs. chronological age that persisted six months after discontinuing treatment. This is to our knowledge the first report of an increase, based on an epigenetic age estimator, in predicted human lifespan by means of a currently accessible aging intervention.
Nextbigfuture covered this work a few days ago. Here we summarize some other antiaging and age reversal work. This is other work being done by other companies.
1. AgeX is working on small molecules and cell lines to package exosomes with mRNA and telomerase to change cells in the body to restore full regeneration and enable antiaging.
2. Juvenescence is creating antiaging therapies using artificial intelligence and biotechnology with a near term goal of extending human lifespan to 150 years. They just raised $100 million in a Series B round, including a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian cofounder), and Michael Spencer’s private investment company, IPGL. This brings the total to $165 Million that Juvenescence has raised in 18 months and speaks to the extraordinary opportunity as well as interest in developing therapeutics with the capacity to modify aging.
They have 12 programs based on hard, rigorous science, to attempt to modify aging. They range from stem cell research to senolytics (removing zombie cells) to modifying or preventing Alzheimer’s and Parkinson’s diseases.
The Juvenescence teams believes within five to seven years at least four anti-aging products will be on the market from their portfolio of about one dozen antiaging companies.
3. Harvard Genetics Giant Geroge Church and Noah Davidsohn, a former postdoc in his lab, have engaged in a secretive antiaging venture called Rejuvenate Bio. They are making old dogs new by reversing aging using a combination of over 40 gene therapy changes. They have conducted gene therapy on beagles and are currently advertising for Cavalier King Charles spaniels to use gene therapy to fix their hearts.
They have identified many other targets for gene-based interventions, studying a database of aging-related genes.
Most of the work was done in mice, where they have extended the life of mice by a factor of two. Nextbigfuture notes that this would mean mice would live 6 years with treatment instead of 3 years.
SOURCES- Juvenescence, UCLA, Aging Cell, Nature, Rejuvenate Bio, AgeX
Written By Brian Wang, Nextbigfuture.com
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.